

## Scientific Paper Platform Presentations, II

### Tuesday, October 23

10:15 a.m.–12:15 p.m.

Diplomat Ballroom 2

*Moderator: Julie Oki Maurey, Pharm.D., FCCP, BCPS*

Director, Regional Medical & Research Specialist, Specialty Care – Pulmonary Vascular Disease, Pfizer, Inc. – U.S. Medical Affairs, Mentor-on-the-Lake, Ohio

#### **41. CHA2DS2-VASc Score Is Associated with Post-cardiothoracic Surgery Atrial Fibrillation.**

*William L. Baker Jr, Pharm.D.,<sup>1</sup> Craig I. Coleman, Pharm.D.,<sup>2</sup> C. Michael White, Pharm.D., FCCP, FCP,<sup>2</sup> Jeffrey Kluger, M.D.<sup>3</sup>; (1)University of Connecticut School of Pharmacy, Farmington, CT; (2)University of Connecticut, Hartford, CT; (3)Hartford Hospital, Hartford, CT*

---

#### **92. Psychotropic Use Monitoring for Nursing Home Residents with Dementia.**

*Kai Zhen Yap, BSP Pharm(Hons),<sup>1</sup> Joyce Y. Lee, Pharm.D.,<sup>1</sup> Ee Heok Kua, MBBS, M.D., FRC Psych, PBM,<sup>2</sup> Sui Yung Chan, BSP Pharm(Hons), MBA, Ph.D.<sup>1</sup>; (1)National University of Singapore, Singapore, Singapore; (2)National University Health System, Singapore, Singapore*

---

#### **94. Does a Pharmacist Care Management Program Improve Hypertension Outcomes in Veterans?**

*Alan J. Zillich, Pharm.D.,<sup>1</sup> Heather A. Jaynes, RN, MSN,<sup>1</sup> Susan D. Bex, Pharm.D., BCPS,<sup>2</sup> Amy S. Boldt, Pharm.D.,<sup>2</sup> Darin C. Ramsey, Pharm.D.,<sup>2</sup> Cassandra M. Walston, Pharm.D.,<sup>2</sup> Dawn M. Bravata, M.D.<sup>2</sup>; (1)Purdue University College of Pharmacy, Indianapolis, IN; (2)Richard L. Roudebush VA Medical Center, Indianapolis, IN*

---

#### **100F. Assessment of Warfarin Requirements in Post-bariatric Surgery Patients.**

*Adriane N. Irwin, Pharm.D., M.S., Kathleen H. McCool, Pharm.D., Thomas Delate, Ph.D., Daniel M. Witt, Pharm.D.; Kaiser Permanente Colorado, Aurora, CO*

---

**150. An Evaluation of the Drug-Drug Interaction Between Proton-Pump Inhibitors and EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients.**

*Alexandre Chan, Pharm.D., MPH,<sup>1</sup> Bingrong Chen, BSPHarm(Hon),<sup>1</sup> Raymond Ng, MBChB, FRACP, MPH,<sup>2</sup> Wei-Peng Yong, MBChB, MRCP,<sup>3</sup> Yu Ko, Ph.D.<sup>1</sup>; (1)National University of Singapore, Singapore, Singapore; (2)National Cancer Centre Singapore, Singapore, Singapore; (3)National University Cancer Institute, Singapore, Singapore*

---

**188F. The Effect of NAD(P)H Dehydrogenase, Quinone 1 Genotype on Warfarin Dose Requirements in Hispanics and African Americans.**

*Adam P. Bress, Pharm.D.,<sup>1</sup> Shitalben R. Patel, M.S.,<sup>2</sup> Minoli Perera, Pharm.D., Ph.D.,<sup>3</sup> Richard T. Campbell, Ph.D.,<sup>1</sup> Rick Kittles, Ph.D.,<sup>1</sup> Larisa H. Cavallari, Pharm.D.<sup>1</sup>; (1)University of Illinois at Chicago, Chicago, IL; (2)University of Illinois at Chicago College of Pharmacy, Chicago, IL; (3)University of Chicago, Chicago, IL*

---

**320. Risk of CMV After r-ATG or IL2 Antagonist Induction and the Impact of CMV-Directed Prophylaxis in Low-Risk Renal Transplant Recipients.**

*Teena Sam, Pharm.D., BCPS,<sup>1</sup> Elise Carlson, Pharm.D.,<sup>2</sup> Ian C. Doyle, Pharm.D., BCPS,<sup>3</sup> Steven Gabardi, Pharm.D., BCPS,<sup>4</sup> Karen L. Hardinger, Pharm.D., BCPS,<sup>5</sup> John Knorr, Pharm.D., BCPS,<sup>6</sup> Lisa M. McDevitt, Pharm.D., BCPS,<sup>7</sup> Kimi Ueda, Pharm.D., BCPS,<sup>8</sup> Eric Tichy, Pharm.D., BCPS<sup>1</sup>; (1)Yale-New Haven Hospital, New Haven, CT; (2)Sanford Health, Fargo, ND; (3)Pacific University Oregon School of Pharmacy, Hillsboro, OR; (4)Department of Pharmacy & Renal Division, Brigham & Women's Hospital; Department of Medicine, Harvard Medical School, Boston, MA; (5)UMKC School of Pharmacy, Kansas City, MO; (6)Albert Einstein Medical Center, Philadelphia, PA; (7)Tufts Medical Center, Boston, MA; (8)California Pacific Medical Center, San Francisco, CA*

---